MA50101A - Agents de modulation des fonctions de la bêta-caténine et méthodes associées - Google Patents

Agents de modulation des fonctions de la bêta-caténine et méthodes associées

Info

Publication number
MA50101A
MA50101A MA050101A MA50101A MA50101A MA 50101 A MA50101 A MA 50101A MA 050101 A MA050101 A MA 050101A MA 50101 A MA50101 A MA 50101A MA 50101 A MA50101 A MA 50101A
Authority
MA
Morocco
Prior art keywords
agents
related methods
modulating beta
catenin functions
catenin
Prior art date
Application number
MA050101A
Other languages
English (en)
Inventor
Gerard Hilinski
John Hanney Mcgee
Paula Ortet
Matthew Reiser Patton
So Youn Shim
Gregory L Verdine
Original Assignee
Fog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fog Pharmaceuticals Inc filed Critical Fog Pharmaceuticals Inc
Publication of MA50101A publication Critical patent/MA50101A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050101A 2017-09-07 2018-09-07 Agents de modulation des fonctions de la bêta-caténine et méthodes associées MA50101A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762555519P 2017-09-07 2017-09-07

Publications (1)

Publication Number Publication Date
MA50101A true MA50101A (fr) 2020-07-15

Family

ID=65635271

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050101A MA50101A (fr) 2017-09-07 2018-09-07 Agents de modulation des fonctions de la bêta-caténine et méthodes associées

Country Status (14)

Country Link
US (2) US11198713B2 (fr)
EP (1) EP3678683A4 (fr)
JP (1) JP2020533413A (fr)
KR (1) KR20200064075A (fr)
CN (1) CN111372942A (fr)
AU (1) AU2018329956A1 (fr)
BR (1) BR112020004555A2 (fr)
CA (1) CA3074838A1 (fr)
EA (1) EA202090513A1 (fr)
IL (1) IL273015A (fr)
MA (1) MA50101A (fr)
MX (1) MX2020002435A (fr)
SG (1) SG11202001162TA (fr)
WO (1) WO2019051327A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018329956A1 (en) 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
CN113557030A (zh) 2018-11-21 2021-10-26 恩多梅特生物科学公司 用于治疗子宫内膜异位症的组合物和方法
WO2021041895A1 (fr) * 2019-08-30 2021-03-04 Ohio State Innovation Foundation Ligands de bêta-caténine agrafés
JP2023535026A (ja) * 2020-07-22 2023-08-15 フォグ ファーマシューティカルズ， インコーポレイテッド ステープルペプチドおよびその方法
JP2024522368A (ja) * 2021-06-08 2024-06-18 フォグ ファーマシューティカルズ， インコーポレイテッド ステープルペプチドおよびその方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0360390A1 (fr) 1988-07-25 1990-03-28 Glaxo Group Limited Dérivés de spirolactames
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
AU1207301A (en) 1999-10-15 2001-04-30 Avatar Medical, Llc Stabilized proteins
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US6822073B2 (en) 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
EP1648873A4 (fr) 2003-03-20 2008-06-25 Neuren Pharmaceuticals Ltd Composes macrocycliques neuroprotecteurs et procedes d'utilisation de ces composes
WO2004093798A2 (fr) 2003-04-18 2004-11-04 Enanta Pharmaceuticals, Inc. Composes macrocycliques de quinoxalinyle inhibant les serine proteases de l'hepatite c
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
EP1680443B9 (fr) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Peptides stabilises structures en helice alpha et leurs utilisations
JP2008510692A (ja) 2004-08-20 2008-04-10 ノボ ノルディスク アクティーゼルスカブ 薬学的に活性なインスリン受容体調節分子
JP2008522954A (ja) 2004-08-20 2008-07-03 フィロジカ リミテッド ｃ−Ｊｕｎ二量化のペプチド阻害剤及びその使用
MX2007007259A (es) 2004-12-20 2007-08-14 Sigma Tau Ind Farmaceuti Inhibidores de homodimerizacion de myd88.
GB0511771D0 (en) 2005-06-09 2005-07-20 Novartis Ag Organic compounds
EP2091552A4 (fr) 2006-11-15 2010-01-06 Dana Farber Cancer Inst Inc Peptides maml stabilisés et leurs utilisations
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
EP2152294B1 (fr) 2007-05-02 2017-07-26 Dana-Farber Cancer Institute, Inc. A bad bh3 domain peptides pour utilisation dans le traitement ou le retardement de l'apparition du diabète.
WO2009020477A1 (fr) 2007-08-06 2009-02-12 Yale University Protéines miniatures modifiées
CA2700925C (fr) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Procedes et compositions pour moduler des polypeptides de la famille bcl-2
ES2629440T5 (es) 2007-10-04 2020-11-20 Zymogenetics Inc zB7H6 miembro de la familia B7 y composiciones y métodos relacionados
EP2247606B1 (fr) 2008-01-23 2019-08-21 Dana-Farber Cancer Institute, Inc. Compositions et méthodes de traitement des infections virales
WO2010011313A2 (fr) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligature de polypeptides agrafés
CN102482336B (zh) 2008-09-22 2015-05-06 爱勒让治疗公司 拟肽大环化合物
WO2010042225A2 (fr) 2008-10-10 2010-04-15 Dana Farber Cancer Institute Modulateurs chimiques des polypeptides bax et bcl-2 pro-apoptotiques
EP3549951A3 (fr) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Procédés et compositions pour la modulation spécifique de mcl-1
EA021794B1 (ru) 2008-12-10 2015-09-30 Ачиллион Фармасьютикалз, Инк. Циклические аналоги 4-амино-4-оксобутаноил пептидов, ингибиторы репликации вирусов
EP2422201B1 (fr) 2009-04-22 2015-04-22 The Walter and Eliza Hall Institute of Medical Research Structure de la region c terminale de la chaîne alpha du recepteur d'insuline et de la chaîne alpha du recepteur de facteur de croissance de type insuline
US9175038B2 (en) 2009-05-15 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
US9296805B2 (en) 2009-06-18 2016-03-29 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
EP3698810A1 (fr) 2009-06-18 2020-08-26 Dana Farber Cancer Institute, Inc. Compositions de peptides viraux structurés et procédés d'utilisation
DE102009032902A1 (de) 2009-07-10 2011-01-13 Forschungsverbund Berlin E.V. Induktion von α-Helix-Konformationen in Proteinen und Peptiden
WO2011008260A2 (fr) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Peptides bifonctionnels insérés et leurs utilisations
EP2528893B1 (fr) 2010-01-29 2018-10-10 Dana-Farber Cancer Institute, Inc. Petites molécules pour la modulation de mcl-1 et procédés de modulation de la mort cellulaire, la division cellulaire, la différenciation cellulaire et procédés de traitement de troubles
US8748570B2 (en) 2010-05-25 2014-06-10 Syngene Limited Insulin analogues
WO2012040459A2 (fr) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Peptides de ciblage de la béta-caténine et leurs utilisations
JP2014502152A (ja) 2010-11-12 2014-01-30 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 癌の治療及び診断
WO2012082891A1 (fr) * 2010-12-14 2012-06-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibiteurs peptidiques synthétiques de la voie wnt
BR112013015389A2 (pt) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp análogo de glucagon exibindo atividade de receptor gip
CA2833171C (fr) 2011-04-15 2021-08-31 Loren D. Walensky Ciblage d'une signalisation wnt deregulee dans le cancer a l'aide d'helices alpha de bcl-9 stabilisees
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
JP2014520120A (ja) 2011-06-17 2014-08-21 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化した変異型ｍａｍｌペプチドおよびその使用
EP3799871B1 (fr) 2011-10-11 2024-02-28 Dana Farber Cancer Institute, Inc. Pyrazol-3-ones activant le bax pro-apoptotique
EP2858661B1 (fr) 2011-12-29 2020-04-22 Dana-Farber Cancer Institute, Inc. Hélices hybrides stabilisées antivirales
AU2013235425B2 (en) 2012-03-20 2017-09-21 Dana Farber Cancer Institute, Inc. Inhibition of MCL-1 and/or BFL-1/A1
US20150198619A1 (en) 2012-09-25 2015-07-16 The Walter And Eliza Hall Institute Of Medical Research Structure of insulin in complex with n- and c-terminal regions of the insulin receptor alpha-chain
DK2920197T3 (da) 2012-09-26 2021-05-31 Harvard College Prolinlåste sammenhæftede peptider og anvendelser deraf
WO2014055564A1 (fr) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Modulateurs stabilisés du récepteur de l'insuline polypeptidique
US9493510B2 (en) 2013-01-10 2016-11-15 Noliva Therapeutics Llc Peptidomimetic compounds
SG10201700952XA (en) 2013-03-13 2017-04-27 Harvard College Stapled and stitched polypeptides and uses thereof
US10087215B2 (en) 2013-03-15 2018-10-02 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
US10308926B2 (en) 2013-03-15 2019-06-04 Dana-Farber Cancer Institute, Inc. Stablized EZH2 peptides
US10106590B2 (en) 2013-03-15 2018-10-23 Dana-Farber Cancer Institute, Inc. BH4 stabilized peptides and uses thereof
US20160122405A1 (en) 2013-06-06 2016-05-05 President And Fellows Of Harvard College Homeodomain fusion proteins and uses thereof
US10227390B2 (en) 2013-06-14 2019-03-12 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
EP3052520A4 (fr) 2013-10-01 2017-12-06 President and Fellows of Harvard College Polypeptides stabilisés et utilisations de ces derniers
US10533039B2 (en) 2014-05-21 2020-01-14 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
AU2016232833A1 (en) 2015-03-18 2017-10-12 Dana-Farber Cancer Institute, Inc. Selective Mcl-1 binding peptides
JP6918712B2 (ja) 2015-07-02 2021-08-11 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化抗微生物性ペプチド
US11078246B2 (en) 2015-08-28 2021-08-03 Dana-Farber Cancer Institute, Inc. Peptides binding to Bfl-1
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
CN108883147B (zh) * 2015-10-05 2023-04-11 北京佳诚生物医药科技开发有限公司 用于治疗异常Wnt信号传送的稳定化BCL9肽
WO2017147283A1 (fr) * 2016-02-23 2017-08-31 Dana-Farber Cancer Institute, Inc. Procédé de génération de peptides de pénétration cellulaire agrafés qui sont dépourvus de propriétés de lyse membranaire non spécifique pour le ciblage thérapeutique
AU2018329956A1 (en) 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
MX2021001943A (es) 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
WO2021119537A1 (fr) 2019-12-11 2021-06-17 Fog Pharmaceuticals, Inc. Technologies utiles pour évaluer la perméabilité
JP2023518413A (ja) 2020-03-17 2023-05-01 フォグ ファーマシューティカルズ， インコーポレイテッド ヘリックス状ステープルペプチドおよびその使用
JP2023535026A (ja) 2020-07-22 2023-08-15 フォグ ファーマシューティカルズ， インコーポレイテッド ステープルペプチドおよびその方法
EP4185284A1 (fr) 2020-07-22 2023-05-31 Fog Pharmaceuticals, Inc. Acides aminés
JP2024522368A (ja) 2021-06-08 2024-06-18 フォグ ファーマシューティカルズ， インコーポレイテッド ステープルペプチドおよびその方法

Also Published As

Publication number Publication date
EA202090513A1 (ru) 2020-08-24
BR112020004555A2 (pt) 2020-09-24
SG11202001162TA (en) 2020-03-30
US20220213154A1 (en) 2022-07-07
WO2019051327A2 (fr) 2019-03-14
US11198713B2 (en) 2021-12-14
US11834482B2 (en) 2023-12-05
EP3678683A4 (fr) 2021-07-14
MX2020002435A (es) 2020-09-22
KR20200064075A (ko) 2020-06-05
JP2020533413A (ja) 2020-11-19
CN111372942A (zh) 2020-07-03
US20200247858A1 (en) 2020-08-06
AU2018329956A1 (en) 2020-08-20
WO2019051327A3 (fr) 2019-04-18
IL273015A (en) 2020-04-30
CA3074838A1 (fr) 2019-03-14
EP3678683A2 (fr) 2020-07-15

Similar Documents

Publication Publication Date Title
MA50101A (fr) Agents de modulation des fonctions de la bêta-caténine et méthodes associées
ZA202004932B (en) Methods and compositions for modulating splicing
EP3617784A4 (fr) Dispositif de modulation de lumière
IL285229A (en) Compounds and methods for modulating RNA function
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
DK3743406T3 (da) Tmem16a modulatorer
HK1249140A1 (zh) 用於調節tmprss6表達的化合物和方法
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
FR3027414B1 (fr) Modulateur de phase electro­optique et procede de modulation
DK3628680T3 (da) Modulering af komplementaktivitet
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
IL264216A (en) Compounds and Methods for Modulating SMN2
MA54386A (fr) Modulateurs de trex1
DK3368046T3 (da) Synthetic composition and method for modulating brain function and behaviour
MA43814A (fr) Anticorps anti-gitr, méthodes et utilisations
FR3027415B1 (fr) Modulateur de phase electro­optique
DK3571193T3 (da) Potassium Channel Modulators
IL256055B (en) Using h3k9me3 modulation to enhance cognitive function
GB2564099B (en) Electro-Optic Modulator
DK3292740T3 (da) Impulsbreddemodulationslyskildestyring og fremgangsmåde
MA53889A (fr) Prothèse ligamentaire
DK3621950T3 (da) Trpv1-modulatorforbindelser
DK3395584T3 (da) Selvklæbende og genanvendelig notits-bærer
GB2575579B (en) Light modulation element
MA43826A (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation